Childhood Cancer Genomics (PDQ®)–Health Professional Version

SECTIONS

Changes to this Summary (12/09/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Leukemias

Added text to state that in newly diagnosed patients with double-mutant CEBPA acute myeloid leukemia (AML), in addition to usual family history queries, germline screening should be considered because 5% to 10% of these patients are reported to have a germline CEBPA mutation (cited Tawana et al. as reference 149).

Added text about miR-155 expression in patients with AML (cited Joyce et al., Marcucci et al., and Ramamurthy et al. as references 274, 275, and 276, respectively).

Non-Hodgkin Lymphoma

Added Swerdlow et al. as reference 27.

Central Nervous System Tumors

The Low-Grade Gliomas section was comprehensively reviewed.

The High-Grade Gliomas section was comprehensively reviewed.

Neuroblastoma

Added Immune system inhibition as a new subsection.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Multiple Endocrine Neoplasia Syndromes

Next section >
About This PDQ Summary